Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer

Condition:   Breast Cancer Intervention:   Other: Prosigna PAM-50 assay Sponsors:   Dana-Farber Cancer Institute;   NanoString Technologies Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials